Interleukin-12 in Treating Patients With Cancer in the Abdomen - Related Studies

Interleukin-12 in Treating Patients With Cancer in the Abdomen

This study is ongoing, but not recruiting participants.

Study NCT00003046. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Anal Cancer
		Carcinoma of the Appendix
		Colorectal Cancer
		Extrahepatic Bile Duct Cancer
		Gallbladder Cancer
		Gastric Cancer
		Gastrointestinal Carcinoid Tumor
		Malignant Mesothelioma
		Pancreatic Cancer
		Small Intestine Cancer

2	Additional conditions recognized in this trial
		Anus Neoplasms
		Bile Duct Neoplasms
		Carcinoid Tumor
		Carcinoma
		Colorectal Neoplasms
		Duodenal Neoplasms
		Gallbladder Neoplasms
		Gastrointestinal Neoplasms
		Ileal Neoplasms
		Intestinal Neoplasms
		Jejunal Neoplasms
		Malignant Carcinoid Syndrome
		Mesothelioma
		Pancreatic Neoplasms
		Stomach Neoplasms

3	More general conditions related to this trial
		Adenocarcinoma
		Adenoma
		Anus Diseases
		Bile Duct Diseases
		Biliary Tract Diseases
		Biliary Tract Neoplasms
		Colonic Diseases
		Digestive System Diseases
		Digestive System Neoplasms
		Duodenal Diseases
		Endocrine Gland Neoplasms
		Endocrine System Diseases
		Gallbladder Diseases
		Gastrointestinal Diseases
		Ileal Diseases
		Intestinal Diseases
		Jejunal Diseases
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms by Site
		Neoplasms, Germ Cell and Embryonal
		Neoplasms, Glandular and Epithelial
		Neoplasms, Mesothelial
		Neoplasms, Nerve Tissue
		Neuroectodermal Tumors
		Neuroendocrine Tumors
		Pancreatic Diseases
		Rectal Diseases
		Rectal Neoplasms
		Stomach Diseases

4	Interventions listed in this trial
		recombinant interleukin-12

5	Additional drug interventions recognized in this trial
		Interleukin-12

6	More general drug interventions related to this trial
		Adjuvants, Immunologic
		Angiogenesis Inhibitors
		Angiogenesis Modulating Agents
		Antineoplastic Agents
		Growth Inhibitors
		Growth Substances
		Immunologic Factors
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

7	Sponsors listed in this trial
		M.D. Anderson Cancer Center
		National Cancer Institute (NCI)